September 1, 2011 -- Merck Serono, the biopharmaceutical division of Merck KGaA, has opened a China lab as part of its planned R&D hub in Beijing. The lab, which has $5.8 million of equipment, will pursue individualized treatments for cancer, neural degenerative disease and autoimmune and inflammatory disorders. More details....
Stock Symbol: (Xetra: MRK)
